Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...

(Reuters) -Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...